000119925 001__ 119925 000119925 005__ 20240319081017.0 000119925 0247_ $$2doi$$a10.1186/s13063-022-06293-x 000119925 0248_ $$2sideral$$a130754 000119925 037__ $$aART-2022-130754 000119925 041__ $$aeng 000119925 100__ $$adel Cura-González, Isabel 000119925 245__ $$aEffectiveness of the MULTIPAP Plus intervention in youngest-old patients with multimorbidity and polypharmacy aimed at improving prescribing practices in primary care: study protocol of a cluster randomized trial 000119925 260__ $$c2022 000119925 5060_ $$aAccess copy available to the general public$$fUnrestricted 000119925 5203_ $$aBackground: The progressive ageing of the population is leading to an increase in multimorbidity and polypharmacy, which in turn may increase the risk of hospitalization and mortality. The enhancement of care with information and communications technology (ICT) can facilitate the use of prescription evaluation tools and support system for decision-making (DSS) with the potential of optimizing the healthcare delivery process. Objective: To assess the effectiveness and cost-effectiveness of the complex intervention MULTIPAP Plus, compared to usual care, in improving prescriptions for young-old patients (65-74 years old) with multimorbidity and polypharmacy in primary care. Methods/design: This is a pragmatic cluster-randomized clinical trial with a follow-up of 18 months in health centres of the Spanish National Health System. Unit of randomization: family physician. Unit of analysis: patient. 000119925 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER/RD16-0001-0004$$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER/RD16-0001-0005$$9info:eu-repo/grantAgreement/ES/ISCIII/PI18-01303$$9info:eu-repo/grantAgreement/ES/ISCIII/PI18-01515$$9info:eu-repo/grantAgreement/ES/ISCIII/PI18-01812 000119925 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000119925 590__ $$a2.5$$b2022 000119925 592__ $$a0.814$$b2022 000119925 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b99 / 136 = 0.728$$c2022$$dQ3$$eT3 000119925 593__ $$aPharmacology (medical)$$c2022$$dQ2 000119925 593__ $$aMedicine (miscellaneous)$$c2022$$dQ2 000119925 594__ $$a3.6$$b2022 000119925 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000119925 700__ $$aLópez-Rodríguez, Juan A. 000119925 700__ $$aLeiva-Fernández, Francisca 000119925 700__ $$0(orcid)0000-0003-2928-6623$$aGimeno-Feliu, Luis A.$$uUniversidad de Zaragoza 000119925 700__ $$aPico-Soler, Victoria 000119925 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000119925 773__ $$g23, 479 (2022), [13 pp.]$$pTrials$$tTrials$$x1745-6215 000119925 8564_ $$s1087286$$uhttps://zaguan.unizar.es/record/119925/files/texto_completo.pdf$$yVersión publicada 000119925 8564_ $$s1963429$$uhttps://zaguan.unizar.es/record/119925/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000119925 909CO $$ooai:zaguan.unizar.es:119925$$particulos$$pdriver 000119925 951__ $$a2024-03-18-15:46:08 000119925 980__ $$aARTICLE